SLC5A2 and acute kidney injury: Furthermore, a systematic review and meta-analysis including 112 randomized controlled trials (totaling over 92,000 patients) and four observational studies (more than 83,900 patients) demonstrated that SGLT2 inhibitors reduce the occurrence of AKI by 36% [30].